

iBio, Inc.  
Form 8-K  
June 23, 2011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **June 20, 2011**

**iBio, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**000-35023**

**26-2797813**

(Commission File Number) (IRS Employer Identification No.)

**9 Innovation Way, Suite 100**

**Newark, Delaware 19711**

(Address of principal executive offices, including zip Code)

**(302) 355-0650**

(Registrant's telephone number, including area code)

**Not applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Edgar Filing: iBio, Inc. - Form 8-K

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(d) Appointment of New Director

Effective June 20, 2011, the Board of Directors (the "Board") of iBio, Inc. (the "Company") voted to appoint Jules A. Müsing to serve on the Board. Mr. Müsing will be one of the Board's Class III directors, whose members' terms expire at the Company's annual meeting to be held in late 2011.

There is no arrangement or understanding between Mr. Müsing and any other person, pursuant to which Mr. Müsing is to be appointed as a director. Mr. Müsing is not a party to any transactions that would require disclosure under Item 404(a) of Regulation S-K.

In connection with his appointment, Mr. Müsing was granted a stock option to purchase 60,000 shares of the Company's common stock under the Company's stock incentive plan, which shall vest in three equal annual installments beginning on the effective date of Mr. Müsing's appointment as director, at an exercise price set at the last trading price on the date of appointment.

On June 22, 2011, the Company issued a press release announcing the appointment of Mr. Müsing. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

Exhibit No. Description

99.1 Press Release of iBio, Inc., issued June 22, 2011

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 22, 2011

IBIO, INC.  
By: /s/ Douglas Beck

Douglas Beck

Chief Financial Officer

---